These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-002109-58 A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 efaproxiral , in Women with Brain Metasta... 2007-06-19 bad-data
Not reported 2006-002811-29 A Multi-center Phase 2 Open-label Study of RS -10-Propargyl-10-Deazaaminopterin pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T ce... 2010-04-21 due-trials
Listed as ongoing, but also has a completion date 2007-004671-19 A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder 2011-09-22 bad-data
Reported results 2007-004673-26 Protocol PDX-012: A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients with Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based... 2011-05-25 due-trials
Listed as ongoing, but also has a completion date 2008-006425-14 Phase 1/2 Study of Pralatrexate in Female Patients with Previously-treated Advanced or Metastatic Breast Cancer 2012-04-23 bad-data
Reported results 2010-022230-81 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Follo... 2015-05-07 due-trials
Completed, but no date Terminated 2011-001309-29 A Multi-center, Open-label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Allos-sponsored Pralatrexate Studies bad-data

Related organisations

Over time organisations can merge, or split.

We think Allos Therapeutics, Inc is now effectively part of Spectrum Pharmaceuticals.